Please try another search
Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company’s lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson’s disease. It targets diseases, such as depression, Alzheimer’s disease, and liver fibrosis due to non-alcoholic steatohepatitis. The company is headquartered in Calgary, Canada.
Name | Age | Since | Title |
---|---|---|---|
J. Roderick Matheson | - | 2021 | Executive Chairman & CEO |
Frank Schweizer | - | 2021 | Member of Scientific Advisory Board |
S. Randall Smallbone | - | 2022 | Independent Director |
Babak Pedram | 42 | 2022 | Independent Director |
Bruce N. Cronstein | - | 2021 | Member of Scientific Advisory Board |
Neil A. Johnson | - | 2021 | Lead Independent Director |
Mark Williams | 51 | 2021 | President, Chief Science Officer & Director |
David Blum | - | 2021 | Member of Scientific Advisory Board |
Jared Young | - | 2021 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review